Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $90.00 short put and a strike $85.00 long put offers a potential 13.64% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $90.00 by expiration. The full premium credit of $0.60 would be kept by the premium seller. The risk of $4.40 would be incurred if the stock dropped below the $85.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is at 67.09 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Allergan (AGN) Earnings Projected to Increase
Fri, 25 Oct 2013 14:05:00 GMT
ADDING MULTIMEDIA FDA Approves JUVÉDERM VOLUMA™ XC
Wed, 23 Oct 2013 20:51:00 GMT
Business Wire – Allergan, Inc., today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVÉDERM VOLUMA™ XC, the first and only filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21.
Weight-Loss Surgery Beats Obesity Better Than Diet, Exercise
Wed, 23 Oct 2013 07:58:14 GMT
Allergan's VISTABEL® (Botulinum Toxin Type A) Receives Europe's First Positive Opinion for Treatment of Moderate to Severe Lateral Canthal Lines (Crow's Feet Lines) in Adult Patients
Tue, 22 Oct 2013 23:01:00 GMT
PR Newswire – MARLOW, England, October 23, 2013 /PRNewswire/ — Positive Opinion Paves the Way for a Second Aesthetic Indication for VISTABEL® in 29 European Countries Today, Allergan Inc. announced that VISTABEL® has …
InnoCore Pharmaceuticals Enters into Exclusive License Agreement with Allergan Related to Development of New Medicines for Ophthalmic Diseases
Tue, 22 Oct 2013 10:19:00 GMT
PR Newswire – GRONINGEN, The Netherlands, October 22, 2013 /PRNewswire/ — InnoCore Pharmaceuticals today announced that it has signed an exclusive License and Collaboration Agreement with Allergan, Inc. (NYSE: AGN), …
Also on Market Tamer…
Follow Us on Facebook